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The cause of schizophrenia is unknown, but it has a significant genetic component. Pharmacologic studies, studies
of gene expression in man, and studies of mouse mutants suggest involvement of glutamate and dopamine neu-
rotransmitter systems. However, so far, strong association has not been found between schizophrenia and variants
of the genes encoding components of these systems. Here, we report the results of a genomewide scan of schizo-
phrenia families in Iceland; these results support previous work, done in five populations, showing that schizophrenia
maps to chromosome 8p. Extensive fine-mapping of the 8p locus and haplotype-association analysis, supplemented
by a transmission/disequilibrium test, identifies neuregulin 1 (NRG1) as a candidate gene for schizophrenia.NRG1
is expressed at central nervous system synapses and has a clear role in the expression and activation of neuro-
transmitter receptors, including glutamate receptors. Mutant mice heterozygous for either NRG1 or its receptor,
ErbB4, show a behavioral phenotype that overlaps with mouse models for schizophrenia. Furthermore, NRG1
hypomorphs have fewer functional NMDA receptors than wild-type mice. We also demonstrate that the behavioral
phenotypes of the NRG1 hypomorphs are partially reversible with clozapine, an atypical antipsychotic drug used
to treat schizophrenia.
Introduction
Schizophrenia (MIM 181500) is a disabling brain dis-
ease affecting 0.5%–1% of the general population. It
has a myriad of manifestations. These classically include
one or more of the following: delusions, disordered
thought, hallucinations, blunted emotions, paranoid ide-
ation, and motor abnormalities such as stereotypic be-
haviors and catatonia (Liddle et al. 1994). More recently,
other cognitive abnormalities—such as impaired mem-
ory, attention, and executive function—have been doc-
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umented (Bilder 1996). Although there are medications
that can alleviate some of these symptoms in patients,
there is no cure available for schizophrenia, and most
patients who respond to current treatments fail to cope
fully in society.
Although conventional antipsychotics act by blocking
dopamine receptors, there is considerable recent evi-
dence linking defects in glutamatergic neurotransmis-
sion to the psychiatric manifestations of schizophrenia.
Antagonists of glutamatergic signaling through the N-
methyl-D-aspartate (NMDA) receptor (such as PCP,
MK-801, and ketamine) induce psychosis in normal in-
dividuals and exacerbate manifestations of schizophre-
nia in patients. Recent studies have shown decreased
binding to subunits of the glutamate receptor and de-
creased expression of subunits of the glutamate receptor
in thalamic nuclei, hippocampus, and dorsal lateral pre-
frontal cortex of schizophrenic patients (Ibrahim et al.
2000; Gao et al. 2000). It is of interest that some of the
atypical antipsychotics (such as clozapine) increase
NMDA-receptor expression and directly facilitate glu-
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tamatergic transmission (Goff and Coyle 2001). Finally,
mice with a reduced number of NMDA receptors ex-
hibit behavior that overlaps that induced by PCP—hy-
peractivity, deficits in social interaction, and decreased
prepulse inhibition (PPI); these are reversible with clo-
zapine (Mohn et al. 1999). It is important to point out,
however, that the glutamate dysfunction hypothesis is
not incompatible with the dopamine hypothesis, be-
cause many reciprocal synaptic relationships exist be-
tween the two systems (Carlsson and Carlsson 1990).
Although the cause of schizophrenia is unknown, fam-
ily and adoption studies suggest that schizophrenia has
a significant genetic component (Cardno et al. 1999;
Tsuang et al. 2001). As in most common diseases, the
inheritance pattern is complex, and the penetrance is low.
Unfortunately, there is no reliable biological marker for
the disease. The many ways that schizophrenia manifests
itself could be explained by locus heterogeneity, which
also may have hampered progress in the search for schizo-
phrenia genes. Given that neurotransmitter pathways are
probably abnormal in schizophrenia, variants of genes
encoding receptor subunits and transporters have been
extensively tested for association to schizophrenia in
many populations (O’Donovan and Owen 1999). Al-
though there have been reports of weak association with
variations of certain genes, no significant findings have
been reproduced in independent cohorts. The associa-
tions reported so far, if real, represent only minor genetic
contributions.
Numerous genomewide linkage scans have been re-
ported for schizophrenia. There is modest evidence for
linkage with several loci, including chromosome 1q, 2,
6, 8p, 13q, and 22q. The chromosome 8p locus (SCZD6
[MIM 603013]) shows suggestive linkage to schizophre-
nia in several different populations (Pulver et al. 1995;
Kendler et al. 1996; Levinson et al. 1996; Blouin et al.
1998; Kaufmann et al. 1998; Shaw et al. 1998; Brzus-
towicz et al. 1999; Gurling et al. 2001). Information on
the LOD scores and the P values in these studies is sum-
marized by Brzustowicz et al. (1999).
Here, we present results of a genomewide scan for
linkage to schizophrenia and a follow-up fine mapping
at a locus on chromosome 8p. Haplotype analysis iden-
tifies neuregulin 1 (NRG1 [MIM 142445]) as a candidate
gene for schizophrenia. Furthermore, we report func-
tional studies supporting the notion that NRG1 plays a
role in the pathogenesis of schizophrenia. First, we con-
firm previous work (Gerlai et al. 2000) showing that mice
hypomorphic for NRG1 (with a different NRG1 mu-
tation than previously phenotyped) exhibit behavioral
abnormalities. Second, we report that mice hypomorphic
for theNRG1 receptor,ErbB4, exhibit similar behavioral
abnormalities. Third, we show that behavioral abnor-
malities of the NRG1 hypomorphs can be partially re-
versed with clozapine. Fourth, our binding studies show
that mice hypomorphic for NRG1 have fewer functional
NMDA receptors than do control mice, which is in keep-
ing with observations made on brains from patients with
schizophrenia (Ibrahim et al. 2000).
Subjects and Methods
Patients
This study was approved by appropriate ethics com-
mittees and the Data Protection Commission of Iceland
(DPC). Informed consent was obtained from all patients
and from their relatives whose blood and DNA samples
were used in the linkage and association analysis. All
personal identifiers associated with medical information
and blood samples were encrypted by the DPC with a
third-party encryption system, as described elsewhere
(Gulcher et al. 2000). The genealogy database was en-
crypted by the DPC in the same manner. Taking part in
the study were 476 patients—including 440 diagnosed
with schizophrenia, 32 with schizoaffective disorder, and
4 with unspecified functional psychosis—as well as un-
affected family members. Most probands were identified
through referrals to the in- and outpatient services of all
three psychiatric departments in Iceland (total popula-
tion 285,000). Diagnoses were assigned according to
Research Diagnostic Criteria (RDC) (Spitzer et al. 1978)
through the use of the lifetime version of the Schizo-
phrenia and Affective Disorders Schedule (SADS-L)
(Spitzer and Endicott 1977). Psychiatrists who were blind
to the genotyping data made consensus diagnoses.
Linkage Analysis
Large multiplex families were collected for the linkage
scan. Pedigrees allowing for up to seven meiotic events
between affected individuals were constructed, using a
clustering algorithm, from an encrypted genealogy da-
tabase that covers the entire Icelandic nation (Gulcher et
al. 2000). A genomewide scan was performed using a
framework map of 950 microsatellite markers and using
protocols described elsewhere (Gretarsdottir et al. 2002).
The marker order and positions for the framework map-
ping set were obtained from our high-resolution genetic
map (Kong et al. 2002). We analyzed the data and de-
termined statistical significance by applying a model in-
dependent affecteds-only allele-sharing method, imple-
mented in the Allegro program, that calculates LOD
scores on the basis of multipoint calculations (Gudbjarts-
son et al. 2000). Our baseline linkage analysis uses the
Spairs scoring function (Kruglyak et al. 1996), the expo-
nential allele-sharing model (Kong and Cox 1997), and
a family-weighting scheme that is halfway, on the log
scale, between weighting each affected pair equally and
weighting each family equally. In the analysis, we treat
all genotyped individuals who are not affected as “un-
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known.” Affecteds are those who are diagnosed, using
the RDC criteria, with schizophrenia, schizoaffective dis-
order, or unspecified functional psychosis.
Physical Mapping
The BAC contig of the region of interest, 8p11-p21,
was generated using the RCPI-11 Human BAC library.
BAC identification and contig orders were determined
by hybridization using available STS markers and mi-
crosatellite markers in the region, followed by successive
rounds of hybridization using markers designed from
BAC end sequences. BAC fingerprint data complemented
these data. Fingerprints of positive clones (FPCs) were
analyzed using the FPC database developed at the Well-
come Trust Sanger Institute. New microsatellite markers
were discovered from cloning and by screening frag-
ments from nebulized BACs.
Identification of At-Risk Haplotypes
To handle missing genotypes and uncertainty with
phase, our own implementation of a likelihood ap-
proach, using the expectation-maximization (EM) al-
gorithm (Dempster et al. 1977) as a computational tool,
was applied to estimate the haplotype frequencies. Under
the null hypothesis, the affected individuals and controls
are assumed to have identical frequencies of all haplo-
types. Under the alternative hypothesis, the candidate
at-risk haplotype is allowed to have a higher frequency
in affected individuals than controls, while the ratios of
the frequencies of all other haplotypes are assumed to
be the same in both groups. Likelihoods are maximized
separately under both hypotheses and a corresponding
1-df likelihood ratio statistic is used to evaluate statis-
tical significance. While our own computer program was
developed to fit our chosen models, and to handle miss-
ing genotypes and haplotypes with many markers effi-
ciently, our use of the EM-algorithm is very similar to
methods used by others (Excoffier and Slatkin 1995;
Hawley and Kidd 1995; Long et al. 1995). Although
applied in a slightly different setting, the 1-df model we
use is essentially that used by Clayton and Jones (1999).
Transmission/Disequilibrium Test
The transmission/disequilibrium test (TDT) was per-
formed on probands for whom both parents are geno-
typed, and one or both parents are heterozygous for the
at-risk haplotype (Spielman et al. 1993).
Sequencing of the NRG1 Locus and Identification of
Exons and Transcripts
BACs covering the minimum tiling path of the region
of interest were analyzed by shotgun cloning and se-
quencing (GenBank accession numbers AF491780 and
TPA BK000383). Dye terminator (ABI PRISM BigDye)
chemistry was used for fluorescent automated DNA se-
quencing. ABI Prism 377 sequencers were used to collect
data, and the Phred/Phrap/Consed and Polyphred soft-
ware packages were used to assemble sequences. We
identified syntenic mouse BACs (library RPCI-23), and,
by BAC walking, a contig across the NRG1 locus was
made. The methods described above were used to sub-
clone and sequence eight syntenic BAC clones from the
mouse. The mouse sequence was used to identify more
exons and potential regulatory elements. Both 3′ and 5′
RACE (rapid amplification of cDNA ends) were per-
formed using the Marathon-Ready cDNA from Clon-
tech Laboratories and cDNA libraries made at deCODE
genetics. cDNA libraries from whole brain, fetal brain,
and testis were screened.
Exon trapping was performed using Exon trapping
system (Live Technologies). Primers were designed for
amplification of candidate exons from cDNA libraries,
touchdown PCRs were performed, and products were
verified by sequencing.
Search for SNPs
Exons were screened by direct sequencing from a PCR
template. Exon sequences and sequences 2 kb upstream
of each transcription start site from 184 patients were
analyzed for SNP detection. Conserved regions within
the 1.5-Mb NRG1 locus sequence (potential regulatory
elements) showing 80% mouse:human identity over
100 bp were screened in 94 patients. SNPs were scored
using a fluorescent-based method (Chen et al. 1999).
Mouse Phenotyping
NRG1 transmembrane-domain–knockout mice were
generated using a targeting vector in which most of exon
11, which encodes the transmembrane domain, and
some of the immediate downstream intron were replaced
with a neomycin resistance gene cassette, preceded by
an oligonucleotide carrying stop codons in each reading
frame and a polyadenylation sequence. The targeting
vector was electroporated into J1 embryonic stem (ES)
cells (129/terSv), and founding chimeras were outcrossed
to C57Bl/6 mice to establish the line. Heterozygous mice
were healthy and fertile, although homozygous embryos
died of cardiac defects around E10.5–E11.5. These mice
will be described more fully elsewhere (R. P. Harvey, D.
Lai, and M. Zhou, unpublished data). ErbB4 hypo-
morphic mice heterozygous for a null allele of the gene
were generated by replacement of the coding region of
exon 2 with a reporter gene (Gassmann et al. 1995).
Heterozygous null NRG1 and ErbB4 mice were bred at
Charles River Laboratories by crossing to a C57Bl/6
background. Six weeks prior to behavioral testing, male
mice and litter-mate control mice for each line were
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shipped to the testing laboratory at PsychoGenics, where
they were housed in groups of three to five related mice
per cage.
The open-field study was conducted when the male
mice were 5–6 mo of age. Group-housed mice were
brought into the experimental room and were allowed
to acclimate for 1 h prior to testing. Each mouse was
placed for 30 min in a square open-field box (17 # 17
# 12 inches). Up to eight animals were tested at one
time, with one animal in each of eight arenas, under low
lighting conditions (provided by a 15-W red lamp). The
automated infrared beam array system measured loco-
motion in the center and periphery of the test arena.
Activity data were collected in 5-min intervals over the
30-min open-field session and were analyzed with a se-
ries of repeated-measures analysis of variance (ANOVA),
with session interval as a within-subject factor and ge-
notype as a between-subject factor. Clozapine (1 mg/kg
in 1% Tween 20, pH 6.0) was injected intraperitoneally
(i.p.) 25 min before behavioral testing. Total activity
data from the study with clozapine were analyzed with
a two-tailed Student’s t test. Experimentally naive mice
were used for these experiments. It seemed that handling
the mice or habituation to the testing conditions changed
the level of hyperactivity or the sensitivity to clozapine
on repeated testing.
The cross maze consisted of an eight-arm radial arm
maze with four of the arms blocked. The maze was
placed on the floor of a dimly lit room (one 25-W lamp)
that had contrasting cues on the wall and on the outside
of the blocked arms of the maze. Each arm measured
14 inches long # 3 inches wide, and the center hub
measured ∼8.5 inches in diameter. Wild-type and het-
erozygous mice were individually placed and tested in
the cross maze for 8 min. Global activity was reflected
in the total number of visits to the different arms. A visit
to an arm was recorded when the body of the mouse
crossed the dividing line between the hub and the arm.
The number of visits to each arm and the order of arm
visits were recorded. Percentages of triple and quadruple
alternations were calculated, where a triple alternation
was the visit of three different arms without entry into
any arm already visited, and quadruple alternation was
the visit to four arms without re-entry (e.g., A-B-C-D,
A-D-C-B, etc., where the letters refer to the arms of the
maze). The percentage was obtained by comparison of
the number of triple or quadruple alternations against
the number of possible triple or quadruple visits.
For assessment of PPI, group-housed mice were brought
into the experimental room and were allowed to acclimate
for a minimum of 1 h prior to testing. Mice were indi-
vidually placed in a startle enclosure in the startle chamber
with a background white noise of 70 dB and were left
undisturbed for 10 min. Then a 16-min session was
started that consisted of 56 trials. Each trial started with
a 50-ms null period, followed by a 20-ms prepulse white
noise of 72, 74, or 78 dB. After a 100-ms delay, the startle
stimulus was presented (a 40-ms 120 dB white noise),
followed by a 290-ms recording time. The total duration
of the trial was 500 ms. Eight types of trials were given:
prepulse (72, 74, or 78 dB) plus startle (10 trials per
prepulse intensity), prepulse (72, 74, or 78 dB) alone (4
trials per prepulse intensity), startle alone (10 trials), and
no stimulation (4 trials). The variable intertrial interval
averaged 15 s (range 10–20 s). In the no-stimulation trials,
baseline measurements were taken. In the startle-alone
trials, the basic auditory startle was measured, and, in the
prepulse-plus-startle trials, the amount of inhibition of
normal startle was measured and was expressed as a per-
centage of the basic startle. In the prepulse-alone trials,
the normal response to a weak noise was measured as a
control. Data from trials in which the latency to the peak
amplitude of the startle was 180 ms were excluded from
the analysis. Animals with a mean startle !100 units were
also excluded from the analysis.
[3H] MK-801 Binding Sites
[3H]-dizocilpine (MK-801) binding in NRG1 hypo-
morphic mice (Gerlai et al. 2000) and control mice was
studied as follows: Wild-type ( ), and NRG1 mu-np 18
tant mice ( ) forebrains were homogenized indi-np 16
vidually at 4C in 25 volumes of Tris-HCl 50 mM, EDTA
10 mM, pH 7.1 buffer with a polytron (10,000 rpm, 30
s). The homogenate was centrifuged at 48,000 g for 10
min, and the pellet was rehomogenized as above and was
incubated for 10 min at 37C. After centrifugation, the
pellet was homogenized as above, and the homogenate
was frozen at 80C. [3H]-dizocilpine saturation iso-
therms were obtained by incubation of various amounts
of the radioligand (0.1–100 nM, final concentration) in
the presence of 10 mg brain membranes for 2 h at room
temperature in a Tris-HCl 5 mM, glycine 100 mM, glu-
tamate 100 mM, pH 7.4 binding buffer. The nonspecific
binding was measured in the presence of 100 mM 1-[1-
(2-thienyl)cyclohexyl]piperidine (TCP). After incubation,
the membranes were filtered on GF/B glass-fiber filters
preincubated for 1 h in a polyethylenimine 0.1% solution.
The filters were washed three times with 3 ml of cold
binding buffer, and the radioactivity bound to the mem-
branes was measured by liquid scintillation counting. The
binding parameters KD and Bmax were obtained from the
fit to the data of the equation of a rectangular hyperbola
(one-site model) by nonlinear regression and were ana-
lyzed by ANOVA.
Results
Schizophrenia Mapped to Chromosome 8p12-p21
The 33 families used for linkage consist of 110 pa-
tients, 105 of whom were available for genotyping. The
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Figure 1 Genomewide scan of 110 patients with schizophrenia from 33 families. The 110 patients included 106 who fulfilled the Research
Diagnostic Criteria (RDC) schizophrenia diagnosis, three patients diagnosed with unspecified functional psychosis, and one diagnosed with
schizoaffective disorder. With the assistance of our genealogical database, the patients were clustered into 33 families, and relations between
patients are as distant as second cousins. The patients and their relatives were genotyped using a framework set of 950 microsatellite markers.
The X-axis gives the genetic distance (in cM) along the chromosome, and the Y-axis gives the LOD score. The data were analyzed using
multipoint allele-sharing, without specification of an inheritance model, using Allegro (Gudbjartsson et al. 2000).
highest initial multipoint LOD score was 3.06, on chro-
mosome 8p at marker D8S532 (fig. 1). Linkage to 8p
has been reported by a number of groups, working with
different populations (Pulver et al. 1995; Kendler et al.
1996; Levinson et al. 1996; Blouin et al. 1998; Shaw et
al. 1998; Kaufmann et al. 1998; Brzustowicz et al. 1999;
Gurling et al. 2001). The region we find to have the
highest LOD score on 8p is 10–15 cM centromeric to
most previously reported linkage to 8p. Low marker
density, low resolution of linkage studies, and uncer-
tainty with maps in many of the older studies may ac-
count for this difference. The work reported here was
done utilizing a high-resolution genetic map that was
not available to the other studies (Kong et al. 2002). It
is, however, possible that this is a distinct locus.
The 8p12-p21 locus was physically mapped using
BACs. The primary goal with the BAC map was to
achieve a high-resolution ordering (100–150 kb) of all
polymorphic markers in a 30-cM region and to facilitate
the search for new polymorphic markers. After adding
extra markers within the linkage peak, thus increasing
the information content, the peak allele-sharing LOD
score for the 33 families declined from 3.06 to 2.53 at
D8S278 (fig. 2). The corresponding multipoint para-
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Figure 2 Fine mapping of the schizophrenia locus on chromosome 8p, with 50 additional markers mapped to the 30-cM locus. Since
correct marker order and genetic distance is essential for multipoint genetic analysis, we determined the order of markers by generating a
physical map of 30 cM in 8p12-p21, using BAC clones, and we determined the genetic distances on our high-resolution genetic map, on the
basis of 1,200 meiotic events (Kong et al. 2002). The solid line represents the allele-sharing LOD score, and the dashed line represents the
parametric LOD score. The additional markers increased the information content from 0.7 to 10.9. The X-axis gives the genetic distance (in
cM) along the chromosome, and the Y-axis gives the LOD score.
metric LOD score was 3.48 when an affecteds-only mul-
tiplicative model was used (i.e., an allele frequency of
0.03 and a six-fold risk, relative to the wild-type, for
every at-risk allele carried). These results constitute only
suggestive linkage to chromosome 8p, but, along with
results of previous studies, they convinced us to search
for haplotypes in this region to assess for association
with schizophrenia.
Haplotype Analysis Identifies NRG1 as a Candidate
Gene for Schizophrenia
We increased the density of microsatellite markers fur-
ther at the 8p locus, to achieve an average density of 1
marker every 75 kb within a 5 cM region centered on
D8S278. For the linkage families, we examined all patient
haplotypes shared identical by descent by multiple pa-
tients within a family, and then we compared these hap-
lotypes across families. Two such haplotypes, each ap-
pearing in multiple families, are shown in figure 3:
microsatellite haplotypes I and II. Shared haplotypes be-
tween families carrying microsatellite haplotype I pointed
us to an ∼600-kb region (fig. 3). To validate the relevance
of the two haplotypes identified and to further narrow
down the region, 373 additional patients were collected
and genotyped, in addition to the patients used in the
linkage analysis. Many of these additional patients had
sporadic disease, or their affected relatives were not alive,
but a fraction of the patients were related. In parallel, we
identified, from our physical map, BACs covering the at-
risk haplotypes (fig. 3) and sequenced them by a shotgun
approach, covering a total of 1.2 Mb, to search for genes
within the region (GenBank AF491780). Within the
boundaries of the at-risk microsatellite haplotypes, we
found a 5′ exon from the NRG1 gene and an EST cluster
with unknown function, Hs.97362 (fig. 3). We have sub-
mitted the complete sequence of the large NRG1 gene to
GenBank (accession number TPA BK000383).
Furthermore, we sequenced the syntenic mouse locus,
1.2 Mb in size, to help identify exons and regulatory
elements. In figure 3, the exon-intron structure of the two
genes is shown schematically, together with the overlap-
ping at-risk microsatellite haplotype I. In the search for
novel exons and genes, we used RT-PCR, 3′ and 5′ RACE,
and exon trapping from BACs covering the NRG1 gene
and 200 kb of the upstream sequence. Novel exons and
splice variants were identified for both genes (H. Ste-
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Figure 3 Microsatellite at-risk haplotypes on chromosome 8p and known genes within a region showing haplotype sharing between 9
of the 33 linkage families. Extensive sharing of two microsatellite haplotypes between patients from the linkage families is shown at the top.
Haplotypes were reconstructed by application of the Allegro program (Gudbjartsson et al. 2000), using available family members to derive the
phase. Key markers in the haplotypes are shown, and the size of the region is indicated. Families carrying the haplotypes are labeled F1–F9,
and the number of affected individuals in each family carrying that haplotype is given in parentheses. Maximum haplotype sharing between
families is 9.5 Mb for haplotype I and 11.4 Mb for haplotype II. Shared haplotypes between families narrow the region of interest to 600 kb
between markers 29H12-7320 and 473C15-439, indicated by a bar (microsatellite haplotype I). The location of a BAC contig covering 1.5 Mb
of the locus region is indicated. The sequence of GS1-57G24 was obtained from the public domain (GenBank accession number AF128834),
but we sequenced the other BACs shown. The positions of NRG1 and an EST cluster of unknown function (Hs.97362) are schematically shown
in relation to the BACs. Exons are indicated by vertical bars.
fansson, V. Steinthorsdottir, J. R. Gulcher, and K. Ste-
fansson, unpublished data).
In an attempt to identify causal alleles, we have screened
all known and novel exons of NRG1 ( ) and ESTnp 25
cluster Hs.97362 ( ) and have identified 15 nonsy-np 8
nonymous SNPs for NRG1 and 3 in the EST cluster
Hs.97362. We have identified two synonymous SNPs and
seven SNPs in the untranslated part of NRG1 and one
synonymous SNP and four SNPs in untranslated regions
of EST cluster Hs.97362. A total of 11,200 SNPs have
been identified in the entireNRG1 sequence (see deCODE
Genetics Web site). All coding SNPs and a number of
SNPs in promoter regions were genotyped for 394 un-
related control individuals and 478 patients. Furthermore,
a number of SNPs identified in conserved regions were
also scored. A total of 58 SNPs were genotyped for all
884 Am. J. Hum. Genet. 71:877–892, 2002
Figure 4 Microsatellite and SNP at-rick haplotypes at the 5′ end of the NRG1 gene. Four haplotypes, defined by 12 SNPs and four
microsatellite markers, were individually found in excess in the schizophrenia patients with similar relative risk. The common core for these
haplotypes, defined by five SNPs and two microsatellite markers, is shown at the bottom. The frequencies for each haplotype in all affected
individuals, independent affected individuals, and control individuals are indicated in the panel on the right. The only known exon within the
boundaries of the core at-risk haplotype is the 5′ exon of GGF2, as indicated in the figure. The distance between the markers flanking possible
recombination breakpoints (arrows) is 290 kb, corresponding to 0.16–0.45 Mb on the scale at the bottom of figure 3.
patients, and, in a subset of patients ( ) and controlnp 94
individuals ( ), an additional 123 SNPs werenp 124
scored for association. A few SNP alleles showed mild
but significant single-marker associations, but they do not
change amino acids or splice sites.
Haplotype analysis was performed as described in
the “Subjects and Methods” section. Unless otherwise
stated, P values reported for association tests are one-
sided, without adjustment for multiple comparisons, and
are based on the EM algorithm. Also, the likelihoods
are computed treating all affected individuals as inde-
pendent. If the affected list includes related individuals,
the estimates of haplotype frequencies are still valid,
whereas the P values calculated would be slightly anti-
conservative. We indicate all such P values with an as-
terisk (*). From the list of all affected individuals, a
smaller list of independent affected individuals is created,
blind to the genotypes, by eliminating first- and second-
degree relatives. Although the P values computed from
such a reduced list is valid, the frequency of a haplotype
that is shared by many affected relatives tends to be
underestimated. We have also used other methods, in-
cluding the Allegro program (Gudbjartsson et al. 2000),
to construct the most likely haplotypes on the basis of
patients and relatives, with comparable results.
No single SNP marker or microsatellite marker was
very statistically significant or had very high estimated
relative risk. The SNP giving the best uncorrected single-
marker association was SNP8NRG221533 ( ).Pp .003
However, a core haplotype consisting of five SNPs
(including SNP8NRG221533) and two microsatellite
markers was identified (P value between 6.7 # 106*
and 8.7 # 105) (fig. 4). Four of the SNP markers
are upstream of the NRG1 gene, but the fifth one
(SNP8NRG433E1006) is coding, changing an arginine
to a glycine in the 5′ exon of glial growth factor 2
(GGF2), which is one of many splice forms of NRG1.
However, the common variant, which is glycine (found
in 88% allelic frequency in case individuals and 85% in
control individuals), is associating with the core at-risk
haplotype and therefore not likely by itself to be the
causative allele. Information on sequence of SNPs and
microsatellites within the NRG1 sequence can be found
at the deCODE Genetics Web site. The core haplotype
covers 290 kb and represents a block of linkage dis-
equilibrium containing the first 5′ exon of NRG1, en-
coding for the amino terminus of GGF2, and upstream
sequences. Close to 90% of this core haplotype can be
accounted for by four extended haplotypes involving 16
markers (fig. 4). Interestingly, whereas HapA in figure
4 corresponds to the extended microsatellite haplotype
I in figure 3 identified in the linkage families, HapB and
HapC (1 and 2), apart from having common alleles for
microsatellite markers 478B14-848 and 420M9-1395,
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tend to have different alleles for many of the microsat-
ellite markers (not all shown in fig. 4). Indeed, at various
intermediate stages before we realized that they share a
core, HapA, HapB, and HapC (1 and 2) were each con-
sidered as independent at-risk haplotypes showing sig-
nificant excess in the patients relative to the control in-
dividuals (fig. 4). The estimates of their risks, relative to
the wild type, are also comparable for HapA and HapB
(relative risk ∼2) and are higher for HapC, but the es-
timate for HapC is based on small numbers (fig. 4).
Hence, we believe that this core haplotype is capturing
an ancestral at-risk haplotype that is represented by a
number of extended microsatellite/SNP haplotypes in the
current population. For the seven markers, that define
the core at-risk haplotype in figure 4, there are only 15
distinct haplotypes with frequencies 1 1% (frequencies
estimated under the null hypothesis with the data from
the patients and controls combined), together account-
ing for 56% of the haplotypes in the population. There
are 65 distinct haplotypes with estimated frequencies
10.1%, together accounting for 94% of haplotypes.
Figure 4 shows the likely locations of historic recom-
bination breakpoints and also reveals that the micro-
satellite marker D8S1810 has probably mutated since
the at-risk SNP haplotype was formed. Haplotypes de-
rived using information from relatives of patients and
controls agreed with these haplotypes derived using the
likelihood approach.
The core at-risk haplotype has an estimated frequency
of 7.5% in the general population and of 15.4% among
all patients with schizophrenia. When a multiplicative
model is assumed, affected individuals are estimated to
have 2.2 times the risk of the wild type for each at-risk
haplotype evaluated. To supplement the results from the
case-control study, we performed the transmission/dis-
equilibrium test (Spielman et al. 1993) and found that,
for parents who were heterozygous with respect to the
core haplotype, there were 33 transmissions to the af-
fected offspring and 17 nontransmissions ( ).Pp .016
Although these results are only marginally significant,
because of the small sample size (parents were not avail-
able for genotyping in many cases), it is heartening that
the ratio of transmissions to nontransmissions is close
to 2:1, which is consistent with the relative risk of 2.2
estimated on the basis of the case-control data.
It is worth noting that the region of interest exhibits
extensive linkage disequilibrium. The core haplotype of
seven markers can be identified by only three markers,
one SNP and two microsatellites. Specifically, if a hap-
lotype includes alleles 1, 0, and 0 for SNP8NRG221533,
478B14-848, and 420M9-1395, respectively, then there
is little uncertainty that it has the corresponding alleles
for the other four markers. Moreover, HapA, HapB, and
HapC in figure 4 each can be captured by only five
markers, the three identifying the core plus microsatellite
markers 29H12-121L21 and D8S1810. Also, HapA is
a good surrogate for the extended microsatellite hap-
lotype I in figure 3. The core at-risk haplotype does not
overlap with EST cluster Hs.97362, suggesting that
NRG1 is the more likely candidate gene in this region.
The EST cluster is 103 kb centromeric to marker
TSC0707290 shown in figure 4. None of the five SNPs
defining the core haplotype is likely to be the causative
SNP, since they do not individually capture the same
degree of association as the core haplotype, they are,
therefore, more likely in linkage disequilibrium with a
causative allele, within the boundaries of the core at-
risk haplotype. Although we have screened 20 kb of the
290-kb core at-risk haplotype for SNPs, including the
known exon and regulatory elements within the core,
there may remain regulatory elements we have not iden-
tified, containing a functional variant that may affect
transcription, RNA splicing, RNA stability, RNA trans-
port, or translation. Alternatively, the functional variant
may include more than one polymorphic site, and a hap-
lotype may be necessary to account for the susceptibility,
as has been suggested for other complex diseases (Drys-
dale et al. 2000; Horikawa et al. 2000). Finally, this may
represent large or small inversions, deletions, or dupli-
cations that have not been uncovered by our mutational
analysis so far.
Microsatellite haplotype II (fig. 3) was found in sub-
stantially higher frequency in patients from the linkage
families than in control individuals (data not shown).
The markers identifying this haplotype overlap with
those of the core haplotype shown in figure 4, but the
alleles are different. This haplotype is rare in control
individuals and in the patients who were not used in the
linkage analysis. Hence, we can currently neither con-
firm nor reject this haplotype as conferring increased
risk.
On the basis of the estimated frequencies and relative
risks reported above, the core haplotype has a popula-
tion attributed risk of 16% when the multiplicative
model is used. It accounts for a 9% increase in risk for
siblings of an affected individual. Hence, its contribution
to the familial risk of schizophrenia, which has been
reported to have ls close to 8.6 (Risch 1990), is small
and cannot fully explain the linkage results we and oth-
ers obtain for this region. Although part of the reason
could be that there are other schizophrenia susceptibility
genes in the 8p region contributing to the LOD scores
and results from linkage analyses have a tendency to
overestimate the contribution of the gene (Goring et al.
2001), we believe there must be other at-risk alleles/
haplotypes of NRG1, probably rarer but possibly with
higher penetrance, yet to be found (e.g., microsatellite
haplotype II). Hence, the overall contribution of NRG1
to schizophrenia may be substantially higher than the
estimate reported here.
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NRG1 and ErbB4 Mutant Mice Display Behavioral
Abnormalities
Schizophrenia is one of the diseases affecting higher
cortical functions for which it has been difficult to de-
velop an animal model that comes close to the human
disease. Indeed, many of the clinical manifestations of
schizophrenia affect mental processes that draw a line
of distinction between humans and other animals. Con-
ventional antipsychotic drugs can be evaluated in ro-
dents, using behavioral assays sensitive to dopaminergic
tone (such as locomotion), yet these have no clear cor-
respondence in the schizophrenic patient. The rank order
of potency of such drugs shows a relatively good cor-
relation between inhibition of dopamine-receptor bind-
ing and clinical benefit (Creese et al. 1976). In addition
to altering dopaminergic function, the newer class of
atypical antipsychotic drugs (e.g., clozapine) have potent
effects on other neurotransmitter systems, including
serotonin.
NRG1 and its receptors, ErbB2, ErbB3, and ErbB4,
are essential genes for development (Gassmann et al.
1995). Homozygous null embryos die at 10.5–11 d of
gestation or soon after birth. Heterozygous null mice,
in contrast, are viable and live to adulthood (Gerlai et
al. 2000). NRG1 hypomorphic mice show hyperactivity
in a number of tests, including the novel open field and
alternating-Y maze, whereas ErbB2 and ErbB3 hetero-
zygous null mice are behaviorally normal. The NRG1
mutant mice used in these studies were generated by a
disruption of the gene targeted so that the epidermal
growth factor (EGF)–like domain is missing (Erickson
et al. 1997). To replicate the abnormal behavioral results
of the reported NRG1 mutant mouse, we carried out
behavioral studies on a second line of NRG1 hetero-
zygous mice (in which the targeted deletion was of exon
11, encoding the NRG1 transmembrane domain [R. P.
Harvey, D. Lai, and M. Zhou, unpublished data]). We
also studied a line of ErbB4 heterozygous null mice
(Gassmann et al. 1995). Quantitation of NRG1 and
ErbB4 mRNA in hippocampus, performed using RT-
PCR, confirmed that 50% reduction of message from
the targeted genes was achieved in both lines of mice.
The NRG1 and ErbB4 heterozygous null mice bred
well, developed normally, and showed generally normal
behavior. The lines were maintained by back crossing
onto C57Bl/6 but were not congenic. When evaluated
in the novel open-field test performed under dim red
light, both types of mice were significantly more active
than their wild-type litter-mate controls, with whom they
had been housed since weaning (figs. 5a and 5b). Because
mice are neophobic and find open spaces aversive, nor-
mal mice will prefer to stay close to the walls (thig-
motaxis), and, indeed, there was no difference between
NRG1 or ErbB4 hypomorphs and their normal litter-
mate controls in measures of anxiety, such as time spent
in the center of the test arena. Hyperactivity in the novel
open-field test was more robust in the NRG1 hypo-
morphs than in the ErbB4 hypomorphs. Hyperactivity
of the NRG1 hypomorphs also was seen in a four-
arm–cross maze test. This is an ethologically based test
that assesses exploratory activity in a novel environment
but does not involve reward delivery. The total number
of entries into one of the four arms of the maze was
increased (37  1.7 vs. 30  1.6, F-test; ). ThePp .01
mice were otherwise behaviorally normal, with no dif-
ference between genotypes in patterns of quadruple or
triple alternations or clockwise or counterclockwise pat-
terns of entry. That the hyperactivity was more robust
in the NRG1 hypomorphs than in the ErbB4 mutant
mice may indicate that the ligand is limiting in the
NRG1/ErbB4 signaling pathway.
Hyperactivity is seen in a number of mutant mice,
particularly those showing an increase in dopaminergic
tone, such as the dopamine transporter (DAT) null mice
(Glickstein and Schmauss 2001), the muscarinic acetyl-
choline–receptor M1 subtype null mice (Gerber et al.
2001), and N-methyl-D-aspartatereceptor subunit NR1
hypomorphic mice (NR1 mice) that express only 10%
of the normal level of NR1 (Mohn et al. 1999). In both
the DAT and NR1 mutants, the hyperactivity is revers-
ible with antipsychotic drugs. Drugs such as clozapine
are sedating at high doses, but, at doses of 1 mg/kg,
they will reverse the hyperactivity in mutant or phar-
macologic models of schizophrenia but will have no ef-
fect on spontaneous activity (O’Neill and Shaw 1999).
To explore reversibility of the hyperactivity of theNRG1
hypomorphs in the two behavioral assays, we tested the
effect of clozapine at a dose of 1 mg/kg on the NRG1
hypomorphs and their normal litter-mate controls. Clo-
zapine at the dose chosen reversed the increased activity
of the NRG1 hypomorphic mice in the novel open-field
test (t-test, ) (see insert in fig. 5a). Clozapine hadP ! .02
no effect on the spontaneous activity of normal mice in
the novel open field and thus was not sedating at that
dose. In the cross maze test, clozapine at 1 mg/kg also
reversed the hyperactivity of the NRG1 hypomorphs.
The total number of entries by the NRG1 hypomorphs
was reduced to baseline in the clozapine-treated animals
(from 36.9  4 in vehicle-treated animals to 27  2 in
clozapine-treated animals; ), whereas clozapinePp .03
had no significant effect on the spontaneous activity of
normal litter-mate control mice in the cross-maze test.
PPI
Although locomotory assays in rodents may have va-
lidity as pharmacologic models for the evaluation of an-
tipsychotic drugs affecting dopaminergic tone, their di-
rect clinical correlate in the schizophrenic patient is
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Figure 5 Locomotion and PPI in NRG1 and ErbB4 hypomorphic mice. NRG1 and ErbB4 hypomorphic mice were significantly more
active, according to different measures that reflect locomotion and exploration. Here, we show distance traveled in a novel open-field test for
the two lines of mice: NRG1 hypomorphic mice (A) and ErbB4 hypomorphic mice (B). Data have been binned into 5-min intervals over the
30-min observation period. Distance traveled was significantly increased in both NRG1 and ErbB4 male mice in comparison to litter-mate
control mice ( NRG1 mice and 22 litter-mate control mice, ; ErbB4 mice and 22 litter-mate control mice, ).np 21 Pp .04 np 39 Pp .03
Open-field activity was monitored as described. Error bars indicate the SEM. A, insert, hyperactivity of the NRG1 mutant mice was reversed
by clozapine. The NRG1 mice and litter-mate control mice were injected i.p. with either clozapine (1 mg/kg) or vehicle, 25 min prior to testing
( NRG1 mice and 10 control mice, ). Open-field activity was monitored as described in the “Subjects and Methods” section.np 10 Pp .02
PPI was recorded for NRG1 (C) and ErbB4 (D) hypomorphic mice, using a conditioning, prepulse noise burst of 72, 74, or 78 dB. NRG1
hypomorphic mice have impaired PPI in comparison to normal, litter-mate control mice (F-test, ), whereas ErbB4 mutant mice werePp .03
not significantly impaired (F-test, ).Pp .056
unclear. On the other hand, a number of studies indicate
that some schizophrenic patients have impaired PPI. This
is a psychometric measure of sensory gating that can be
evaluated in similar fashion in rodents and humans
(Braff and Geyer 1990). We find that PPI is impaired in
the NRG1 hypomorphic mice and less so in the ErbB4
mutant mice. The auditory/perceptual systems of NRG1
and ErbB4 hypomorphic mice are generally intact, since
both show normal acoustic startle responses to a single
noise burst of 120 dB. With respect to PPI, however,
NRG1 hypomorphic mice were impaired in comparison
to normal litter-mate controls (F-test, ) (fig. 5c).Pp .03
However, the ErbB4 hypomorphs did not show signif-
icant difference in PPI (F-test, ) (fig. 5d). ThePp .056
defect in PPI in NRG1 hypomorphic mice was not re-
versed by clozapine at a dose of 1 mg/kg, although these
studies need to be expanded.
16% Fewer Functional NMDA Receptors in the NRG1
Mutant Mice
We performed MK-801 binding studies of forebrain
homogenates from NRG1 hypomorphs generated by
Gerlai et al. (2000) and control mice. The pKD values
were analyzed by ANOVA and did not reveal any dif-
ferences between the wild-type and the mutant mice.
Bmax values (pmoles/mg protein) in the mutants were
found to differ significantly (one-sided ) fromPp .0068
those in the wild-type mice, suggesting that there are
16% fewer functional NMDA receptors in the mutant
animals overall (table 1). This is in keeping with reports
suggesting a role for NRG1 in regulation of NMDA
subunit expression (Ozaki et al. 1997).
It is also of interest here that there appears to be re-
duction in the numbers of functional NMDA receptors







NRG1 knockout 16 1.23 # 1012 2.22 # 1013 6.8 # 103
Wild type 18 1.43 # 1012 2.14 # 1013
NOTE.—Concentrations of [3H] MK801 in homogenates from forebrains
of NRG1 knockout and wild-type mice. One-sided P value is given.
in certain regions of brains from schizophrenic individ-
uals (Ibrahim et al. 2000; Goff and Coyle 2001). We
feel, however, that we have to caution that this does not
necessarily mean that the principal pathogenic alteration
in schizophrenia lies in the glutamate system.
Discussion
NRG1 Provides a Way of Unifying a Large Body of
Conflicting Evidence
Through the work described above, we have identified
the NRG1 gene as a strong candidate for a gene playing
a role in the pathogenesis of schizophrenia. We present
three lines of evidence in support of this role for NRG1.
The first is genetic evidence, consisting of suggestive
linkage of schizophrenia to chromosome 8p in Icelandic
families, supported by suggestive linkage in other pop-
ulations (Pulver et al. 1995; Kendler et al. 1996; Lev-
inson et al. 1996; Blouin et al. 1998; Shaw et al. 1998;
Kaufmann et al. 1998; Brzustowicz et al. 1999; Gurling
et al. 2001). This evidence is further supported by highly
significant association of overlapping haplotypes that
contain only one known gene within the overlap, namely
NRG1. The population attributed risk for the identified
core haplotype is 16%, which is a substantial contri-
bution to the public health burden. The weakness in the
genetic evidence is that we have not yet found a clear
pathogenic mutation, which may, however, be par for
the course in the genetics of common diseases.
The second line of evidence is that mice hypomorphic
for each of two mutations in NRG1 and one mutation
in a receptor for NRG1 display behavior that overlaps,
in part, with mouse models for schizophrenia, and this
is reversed, in part, with clozapine in a NRG1 mutant
line.
The third line of evidence is that the number of
NMDA receptors in the NRG1 hypomorphs is reduced
which is in keeping with observations made on brains
from schizophrenia patients. Thus, these results argue
that variants of the NRG1 gene contribute to the path-
ogenesis of schizophrenia in some patients, probably
through a decrease in NRG1 signaling. The overlap in
behavioral phenotype between the NRG1 and ErbB4
hypomorphic mice, and the lack of a similar behavioral
phenotype in ErbB2 or ErbB3 mice (Gerlai et al. 2000),
argues that the defect is primarily neuronal. Although
each line of evidence is not conclusive, they constitute,
when put together, a strong case for NRG1 as a culprit
in the pathogenesis of schizophrenia. Furthermore, the
NRG1 knockout mice provide a tool to explore this
hypothesis further, on the basis of our understanding of
the genetics of the disease.
The NRG1 gene was identified as a schizophrenia
gene by using a combination of a linkage and association
approaches, based on microsatellite markers and then
SNPs once microsatellite at-risk haplotypes were iden-
tified. Although SNP haplotypes are in general more sta-
ble and may capture the ancestral haplotype better than
the overriding microsatellites, at-risk haplotypes in our
study would not have been identified in a systematic
manner without using the more cost-effective and in-
formative microsatellite markers. In fact, our core at-
risk haplotype is best represented by a combination of
two stable microsatellites and one SNP.
Despite finding 11,200 SNPs in the NRG1 gene and
scoring 181 for association, we failed to find a clear
functional polymorphism that captures the same degree
of association as the schizophrenia at-risk core haplo-
type. SNPs screened were found within exons, promot-
ers, splice sites, and regions of the gene most homolo-
gous between mouse and human. Our core at-risk
haplotype represents a block of linkage disequilibrium
that can be represented by just a few SNP and micro-
satellite markers. We continue to screen the large introns
and flanking regions of the gene for associated varia-
tions, especially within the regions most conserved with
the mouse.
NRG1 has not previously been considered in the con-
text of schizophrenia. However, it is a fascinating can-
didate gene for the disease. A unique strength of the
hypothesis that a defect in neuronal NRG1 signaling
underlies some cases of schizophrenia is that it brings
together the disparate clinical and pathological features
of this disease into a common pathway. NRG1 isoforms
(also called “ARIA,” “GGF2,” “NDF,” “SMDF,” and
“heregulin,” depending on the isoform and tissue in
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which they were first identified) are a group of proteins
that arise from alternative splicing of a single primary
transcript (Fischbach and Rosen 1997; Wang et al.
2001). NRG1 isoforms are expressed in many tissues,
including the CNS, and these isoforms clearly have a
developmental role, as indicated by knockout mice dis-
playing severe developmental anomalies in the heart and
the nervous system (Liu et al. 1998; Gerlai et al. 2000).
An NRG1 isoform originally discovered on the presy-
naptic membrane of the motor neuron (as ARIA) was
found to be the factor inducing expression and locali-
zation of acetylcholine receptors (AchR) at the neuro-
muscular synapse. NRG1 isoforms influence gliogenesis
and neuronal migration during development of the
brain, and, in the adult nervous system, NRG1 appears
to have a marked impact on the expression and acti-
vation of several neurotransmitter receptors, including
NMDA glutamate receptors (Ozaki et al. 1997; Ibra-
him et al. 2000), possibly Ca2-activated K channels
(Chu et al. 1995; Cameron et al. 2001), and it al-
so facilitates neurotransmitter release from GABAergic
interneurons.
The transmembrane forms of NRG1 are present
within synaptic vesicles, including those containing glu-
tamate. After exocytosis, NRG1 is in the presynaptic
membrane, where the ectodomain of NRG1 may be
cleaved off. The ectodomain then migrates across the
synaptic cleft and binds to and activates a member of
the EGF-receptor family on the postsynaptic membrane.
This has been shown to increase the expression of certain
glutamate-receptor subunits. In addition, ErbB4, the
predominant receptor for NRG1 on CNS neurons, is
colocalized with NMDA receptors in the postsynaptic
density 95 complex (Garcia et al. 2000; Huang et al.
2000). In the CNS, the NMDA subunits, NR2A and
NR2B, are heavily phosphorylated at tyrosine residues
(Lau and Huganir 1995), and this posttranslational
modification enhances receptor activity by altering the
kinetic properties of the channel (Lau and Huganir
1995). Garcia et al. (2000) pointed out the possibility
that the activity-dependent activation of ErbB4 recep-
tors by NRG1 may regulate synaptic plasticity by re-
cruiting tyrosine kinases that regulate NMDA receptor
function. Thus, NRG1 appears to signal for glutamate-
receptor subunit expression, localization, and /or phos-
phorylation facilitating subsequent glutamate transmis-
sion. Therefore, the activity-dependent effects of NRG1
and ErbB4 on glutamatergic transmission efficiency may
be one mechanism of synaptic plasticity. Abnormalities
in synaptic plasticity may lead to the abnormalities in
thought processes and cognition seen in schizophrenia
that is out of proportion to the subtle decrease in glu-
tamate receptors.
There are many pharmacologic and mouse mutant
data that support the glutamate dysfunction hypothesis,
and glutamate-receptor expression and binding may be
decreased in schizophrenia patients (Huang et al. 2000).
However, studies looking for variations in receptor sub-
units have not shown clear association to schizophrenia.
Hypofunction ofNRG1 in schizophrenia, could explain,
in part, the apparent deficiency in glutamate-receptor
expression and binding described within in some parts
of brains of schizophrenia patients (Huang et al. 2000).
NRG1 has additional roles in AchR expression. Ab-
normalities in PPI, the sensory gating of which may be
mediated by nicotinic AchR in the hippocampus (Freed-
man et al. 1995; Holt et al. 1999) as well as the high
rate of nicotine addiction in schizophrenic patients could
be secondary to NRG1 abnormalities. Thus, it is also
possible that the NRG1 abnormality causes schizophre-
nia through a mechanism in which the glutamate system
plays a minor role.
Our behavioral data on the NRG1 and ErbB4 mouse
mutants provide additional evidence for a role of NRG1
in schizophrenia. We replicate the work done by Gerlai
et al. (2000) on a different NRG1 mutant and we show
that both the NRG1 and the ErbB4 hypomorph mice
are hyperactive, a phenotype that overlaps with behav-
iors induced by PCP in normal mice. Clozapine reduced
the hyperactivity in the NRG1 mice as it does in PCP-
treated mice and mice with reduced numbers of
NMDAR1 (NR1)–receptor subunits (Mohn et al. 1999).
The clozapine reversal, therefore, further supports the
possibility that the hyperactivity observed in the NRG1
mice is related to schizophrenic phenotypes. In addition,
the NRG1 mice showed a defect in PPI, a psychomotor
defect seen in some schizophrenic patients that can be
evaluated in animals in a similar fashion.
Heterozygous ErbB2 and ErbB3 knockouts do not ex-
hibit behavior abnormalities (Gerlai et al. 2000), but
ErbB4 is the predominant neuronal receptor for NRG1
in the CNS (Steiner et al. 1999). It is not clear, at this
point, how NRG1 contributes to schizophrenia suscep-
tibility, and it is likely that additional factors, such as
environmental stress or variants of interacting genes, may
be required to unmask the disease. Nevertheless, the avail-
ability ofNRG1 andErbB4 hypomorphic mice offers new
opportunities for exploration of genetic and environmen-
tal interactions that may contribute to the pathogenesis
of schizophrenia and for the development of novel
therapies.
In summary, we have presented linkage, case-control
haplotype-association, and TDT analyses that support
the notion that NRG1 contributes to schizophrenia. In
addition, we present behavioral and pharmacological
data on mouse mutants of NRG1 and ErbB4, as well
as glutamate-receptor–binding data supporting its pro-
posed role in schizophrenia.
If NRG1 is a schizophrenia susceptibility gene, its im-
pact is unlikely to be limited to the Icelandic population,
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since schizophrenia has been linked to 8p in other pop-
ulations. NRG1 provides a way of unifying a large body
of evidence coming from many directions, suggesting
that multiple neurotransmitter systems and their recep-
tors are involved in schizophrenia by representing a
common denominator upstream of neurotransmitter ex-
pression and activation. Furthermore, it may provide
support for the view that schizophrenia is caused by
disregulation of synaptic plasticity in the adult.
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